{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:39:48Z","timestamp":1792269588895,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) involving multiple organs. However, delayed-onset, multisystem irAEs after treatment discontinuation are uncommon. Here, we present a rare case of a man in his 50s with microsatellite instability-high colon cancer who developed multisystem irAEs following treatment with nivolumab plus ipilimumab. The patient developed adrenocorticotropic hormone deficiency after four cycles of combination therapy, which improved with hydrocortisone supplementation. Following eight cycles of nivolumab monotherapy, treatment was discontinued because no cancerous lesions were detected. Six months after the final nivolumab administration, the patient presented with bilateral knee arthritis and elevated hepatobiliary and pancreatic enzyme levels. No evidence of infectious, autoimmune, or IgG4-related disease was found. Liver biopsy revealed portal lymphocytic infiltration with a predominance of CD8-positive cells. The patient was diagnosed with delayed ICI-related arthritis, accompanied by asymptomatic cholangitis and pancreatitis. These irAEs improved rapidly after prednisolone administration. This case demonstrates that irAEs can occur in a delayed and multisystem manner, even after the cessation of ICIs. Thus, clinicians should consider irAEs in the differential diagnosis when new symptoms or unexplained laboratory abnormalities occur in patients with prior ICI exposure.<\/jats:p>","DOI":"10.1007\/s12328-026-02460-8","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:12:30Z","timestamp":1790575950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Delayed and multisystem immune-related adverse events in MSI-high colon cancer treated with nivolumab plus ipilimumab"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7529-9375","authenticated-orcid":false,"given":"Takato","family":"Maeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Numao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Hanabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Shimaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Fukutoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2460_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","volume":"36","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025;36:277\u201384.","journal-title":"Ann Oncol"},{"key":"2460_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","volume":"405","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Elez E, Lenz HJ, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405:383\u201395.","journal-title":"Lancet"},{"key":"2460_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"2460_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primer. 2020;6:38.","journal-title":"Nat Rev Dis Primer"},{"key":"2460_CR5","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","volume":"6","author":"B Shankar","year":"2020","unstructured":"Shankar B, Zhang J, Naqash AR, et al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol. 2020;6:1952\u20136.","journal-title":"JAMA Oncol"},{"key":"2460_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/curroncol31010028","volume":"31","author":"Y Li","year":"2024","unstructured":"Li Y, Pond G, McWhirter E. Multisystem immune-related adverse events from dual-agent immunotherapy use. Curr Oncol. 2024;31:425\u201335.","journal-title":"Curr Oncol"},{"key":"2460_CR7","doi-asserted-by":"publisher","first-page":"1399171","DOI":"10.3389\/fonc.2024.1399171","volume":"14","author":"C Olsson Ladjevardi","year":"2024","unstructured":"Olsson Ladjevardi C, Koliadi A, Ryd\u00e9n V, et al. Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness. Front Oncol. 2024;14:1399171.","journal-title":"Front Oncol"},{"key":"2460_CR8","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis P, Jochum F, Abbar B, et al. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u2014a worldwide perspective. eClinicalMedicine. 2024;70:102536.","journal-title":"eClinicalMedicine"},{"key":"2460_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41698-025-01123-0","volume":"9","author":"Y Wang","year":"2025","unstructured":"Wang Y, Guo Y, Tan AC, et al. A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors. NPJ Precis Oncol. 2025;9:346.","journal-title":"NPJ Precis Oncol"},{"key":"2460_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s40425-019-0727-5","volume":"7","author":"N Shah","year":"2019","unstructured":"Shah N, Jacob J, Househ Z, et al. Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab. J Immunother Cancer. 2019;7:247.","journal-title":"J Immunother Cancer"},{"key":"2460_CR11","doi-asserted-by":"publisher","first-page":"592609","DOI":"10.3389\/fonc.2020.592609","volume":"10","author":"J Matull","year":"2020","unstructured":"Matull J, Livingstone E, Wetter A, et al. Durable complete response in a melanoma patient with unknown primary, associated with sequential and severe multi-organ toxicity after a single dose of CTLA-4 plus PD-1 blockade: A Case Report. Front Oncol. 2020;10:592609.","journal-title":"Front Oncol"},{"key":"2460_CR12","doi-asserted-by":"publisher","first-page":"664809","DOI":"10.3389\/fonc.2021.664809","volume":"11","author":"C Deng","year":"2021","unstructured":"Deng C, Yang M, Jiang H, et al. Immune-related multiple-organs injuries following ICI treatment with tislelizumab in an advanced non-small cell lung cancer patient: A Case Report. Front Oncol. 2021;11:664809.","journal-title":"Front Oncol"},{"key":"2460_CR13","first-page":"e18040","volume":"13","author":"SJ Bawek","year":"2021","unstructured":"Bawek SJ, Ton R, McGovern-Poore M, et al. Nivolumab-induced myasthenia gravis concomitant with myocarditis, myositis, and hepatitis. Cureus. 2021;13:e18040.","journal-title":"Cureus"},{"key":"2460_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12902-021-00693-x","volume":"21","author":"C Newman","year":"2021","unstructured":"Newman C, Kgosidalwa O, Hakami OA, et al. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature. BMC Endocr Disord. 2021;21:33.","journal-title":"BMC Endocr Disord"},{"key":"2460_CR15","doi-asserted-by":"publisher","first-page":"799077","DOI":"10.3389\/fimmu.2021.799077","volume":"12","author":"X Hu","year":"2021","unstructured":"Hu X, Wei Y, Shuai X. Case report: glucocorticoid effect observation in a ureteral urothelial cancer patient with ICI-associated myocarditis and multiple organ injuries. Front Immunol. 2021;12:799077.","journal-title":"Front Immunol"},{"key":"2460_CR16","doi-asserted-by":"publisher","first-page":"530","DOI":"10.14740\/jmc4008","volume":"13","author":"A Schwab","year":"2022","unstructured":"Schwab A, Assaad M, Hamadi R, et al. Pembrolizumab-induced myasthenia gravis and myositis: literature review on neurological toxicities of programmed death protein 1 inhibitors. J Med Cases. 2022;13:530\u20135.","journal-title":"J Med Cases"},{"key":"2460_CR17","first-page":"e35871","volume":"15","author":"HS Ahdi","year":"2023","unstructured":"Ahdi HS, Abdulmujeeb S, Nabrinsky E. Multiple autoimmune complications after a single dose of pembrolizumab. Cureus. 2023;15:e35871.","journal-title":"Cureus"},{"key":"2460_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.anl.2022.02.002","volume":"50","author":"K Aoki","year":"2023","unstructured":"Aoki K, Hamamoto T, Chikuie N, et al. Severe multiple simultaneous immune-related adverse events in a patient with head and neck cancer. Auris Nasus Larynx. 2023;50:309\u201313.","journal-title":"Auris Nasus Larynx"},{"key":"2460_CR19","first-page":"e41781","volume":"15","author":"D Brazel","year":"2023","unstructured":"Brazel D, Lee S, Mahadevan A, et al. Multiorgan failure from nivolumab and ipilimumab: a case report and literature review. Cureus. 2023;15:e41781.","journal-title":"Cureus"},{"key":"2460_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.22551\/2025.46.1201.10306","volume":"12","author":"MR Han","year":"2025","unstructured":"Han MR, Lee CH, Jeon SY, et al. Pembrolizumab-induced simultaneous and multiple immune-related adverse events including myasthenia gravis, myositis, hepatitis, and pityriasis lichenoides in a non-small cell lung cancer patient. Arch Clin Cases. 2025;12:17\u201321.","journal-title":"Arch Clin Cases"},{"key":"2460_CR21","doi-asserted-by":"publisher","first-page":"1508293","DOI":"10.3389\/fimmu.2025.1508293","volume":"16","author":"M Yuan","year":"2025","unstructured":"Yuan M, Han N, Shu L, et al. Case report: multi-organ injuries induced by tislelizumab. Front Immunol. 2025;16:1508293.","journal-title":"Front Immunol"},{"key":"2460_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1159\/000547066","volume":"19","author":"B Kalifu","year":"2025","unstructured":"Kalifu B, Meng Y, Aishanjiang K, et al. Overlapping syndrome of myocarditis, myositis, transaminitis, and myasthenia gravis in a patient with hepatocellular carcinoma after treatment with immune checkpoint inhibitors: a Case report and literature review. Case Rep Gastroenterol. 2025;19:611\u201320.","journal-title":"Case Rep Gastroenterol"},{"key":"2460_CR23","doi-asserted-by":"publisher","first-page":"1679328","DOI":"10.3389\/fimmu.2025.1679328","volume":"16","author":"R Jiao","year":"2025","unstructured":"Jiao R, Wang C, Ying H, et al. Case report of immune checkpoint inhibitor induced cholestatic hepatitis, acute renal injury and asymptomatic pancreatic enzyme elevation simultaneously. Front Immunol. 2025;16:1679328.","journal-title":"Front Immunol"},{"key":"2460_CR24","doi-asserted-by":"publisher","first-page":"1677544","DOI":"10.3389\/fimmu.2025.1677544","volume":"16","author":"NL Varada","year":"2025","unstructured":"Varada NL, Yang O, Savage DJ. Case report: multiple immune related adverse events in a patient with metastatic melanoma. Front Immunol. 2025;16:1677544.","journal-title":"Front Immunol"},{"key":"2460_CR25","doi-asserted-by":"publisher","first-page":"879900","DOI":"10.3389\/fimmu.2022.879900","volume":"13","author":"X Xie","year":"2022","unstructured":"Xie X, Wang L, Li Y, et al. Multi-organ immune-related adverse event is a risk factor of immune checkpoint inhibitor-associated myocarditis in cancer patients: a multi-center study. Front Immunol. 2022;13:879900.","journal-title":"Front Immunol"},{"key":"2460_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/1751-2980.13122","volume":"23","author":"T Yamamoto","year":"2022","unstructured":"Yamamoto T, Ito T, Mizuno K, et al. A case of antiprogrammed death-ligand 1 antibody\u2010induced multisystem immune\u2010related adverse events with pancreatitis and steroid\u2010resistant sclerosing cholangitis. J Dig Dis. 2022;23:404\u20139.","journal-title":"J Dig Dis"},{"key":"2460_CR27","doi-asserted-by":"publisher","first-page":"e9153","DOI":"10.1002\/ccr3.9153","volume":"12","author":"M Yamano","year":"2024","unstructured":"Yamano M, Hamakawa M, Akaike Y, et al. A case report of immune checkpoint inhibitor-related myositis and cholangitis induced by pembrolizumab. Clin Case Rep. 2024;12:e9153.","journal-title":"Clin Case Rep"},{"key":"2460_CR28","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1007\/s00261-025-04994-w","volume":"50","author":"K Kawata","year":"2025","unstructured":"Kawata K, Inoue D, Komori T, et al. Case of simultaneous occurrence of hepatitis, cholangitis, and pancreatitis as immune-related adverse events induced by immune checkpoint inhibitor therapy: a case report. Abdom Radiol. 2025;50:5845\u201351.","journal-title":"Abdom Radiol"},{"key":"2460_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","volume":"26","author":"T Onoyama","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol. 2020;26:353\u201365.","journal-title":"World J Gastroenterol"},{"key":"2460_CR30","doi-asserted-by":"publisher","first-page":"eadd1591","DOI":"10.1126\/sciimmunol.add1591","volume":"8","author":"R Wang","year":"2023","unstructured":"Wang R, Singaraju A, Marks KE, et al. Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis. Sci Immunol. 2023;8:eadd1591.","journal-title":"Sci Immunol"},{"key":"2460_CR31","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","volume":"186","author":"P Caturegli","year":"2016","unstructured":"Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016;186:3225\u201335.","journal-title":"Am J Pathol"},{"key":"2460_CR32","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00262-022-03295-1","volume":"72","author":"M Ashkar","year":"2023","unstructured":"Ashkar M, Chandra S, Vege SS, et al. Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification. Cancer Immunol Immunother. 2023;72:895\u2013901.","journal-title":"Cancer Immunol Immunother"},{"key":"2460_CR33","doi-asserted-by":"publisher","first-page":"e006398","DOI":"10.1136\/jitc-2022-006398","volume":"11","author":"J Naidoo","year":"2023","unstructured":"Naidoo J, Murphy C, Atkins MB, et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer. 2023;11:e006398.","journal-title":"J Immunother Cancer"},{"key":"2460_CR34","doi-asserted-by":"publisher","first-page":"e009902","DOI":"10.1136\/jitc-2024-009902","volume":"12","author":"R Noseda","year":"2024","unstructured":"Noseda R, Bedussi F, Giunchi V, et al. Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase. J Immunother Cancer. 2024;12:e009902.","journal-title":"J Immunother Cancer"},{"key":"2460_CR35","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3390\/cancers17152461","volume":"17","author":"J Pozas","year":"2025","unstructured":"Pozas J, Cheruvu S, Jaganathan PP, et al. Late-onset immune-related adverse events in patients with advanced melanoma: The LATENT Study. Cancers. 2025;17:2461.","journal-title":"Cancers"},{"key":"2460_CR36","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02460-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:12:31Z","timestamp":1790575951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02460-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":36,"alternative-id":["2460"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02460-8","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}